Mel Mann, World’s Longest Living Gleevec (Imatinib) & Tyrosine Kinase Inhibitor Survivor, 31-year terminal Chronic Myeloid Leukemia (CML) Survivor, Clinical Trial Pioneer, and Patient Advocate, shared on X:
“Cancer research funding isn’t optional.
It’s the difference between no options left’ and ‘there’s still a path’.
Every cut delays a trial.
Every delay costs lives.
Fund the science. Protect the patients.
Research is non-negotiable.”
